Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - methylphenidathydrochlorid - depottabletter - 54 mg

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - risperidon - depotinjektionsvæske, pulver og solvens til suspension - 37,5 mg

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - risperidon - depotinjektionsvæske, pulver og solvens til suspension - 50 mg

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 100 mikrogram/time

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 25 mikrogram/time

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 50 mikrogram/time

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 75 mikrogram/time

Европейски съюз - датски - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Европейски съюз - датски - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - hiv infektioner - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, er indiceret i kombination med andre antiretrovirale lægemidler til behandling af human immunodeficiency virus 1 (hiv 1) infektion hos voksne i alderen 18 år eller derover. genotypiske test bør vejlede i brugen af rezolsta.

Европейски съюз - датски - EMA (European Medicines Agency)

janssen-cilag international nv - bedaquilinfumarat - tuberkulose, multidrugt-resistent - antimyco-bakterielle midler - sirturo er indiceret til brug som en del af en passende kombination regime for pulmonal multidrug resistente tuberkulose (mdr-tb) hos voksne og unge patienter (12 år til mindre end 18 år, og som vejer mindst 30 kg), når en effektiv behandling regime ellers ikke kan være sammensat på grund af resistens eller tolerance. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..